Miriam L Greenberg Selected Research

Cardiolipins (Cardiolipin)

1/2022	NAD supplementation improves mitochondrial performance of cardiolipin mutants.
1/2022	Current Knowledge on the Role of Cardiolipin Remodeling in the Context of Lipid Oxidation and Barth Syndrome.
1/2021	Studying Lipid-Related Pathophysiology Using the Yeast Model.
1/2018	Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
1/2017	Barth syndrome: A life-threatening disorder caused by abnormal cardiolipin remodeling.
1/2017	Cardiolipin Regulates Mitophagy through the Protein Kinase C Pathway.
4/2014	The functions of cardiolipin in cellular metabolism-potential modifiers of the Barth syndrome phenotype.
2/2014	Deletion of the cardiolipin-specific phospholipase Cld1 rescues growth and life span defects in the tafazzin mutant: implications for Barth syndrome.
12/2009	Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome.
12/2008	Cardiolipin mediates cross-talk between mitochondria and the vacuole.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Miriam L Greenberg Research Topics

Disease

16	Barth Syndrome 01/2022 - 01/2004
7	Bipolar Disorder (Manic Depressive Psychosis) 01/2017 - 09/2003
6	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 10/2004
4	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 06/2007
3	Starvation 01/2017 - 11/2015
2	Mental Disorders (Mental Disorder) 01/2020 - 11/2014
2	Epilepsy (Aura) 11/2015 - 01/2012
2	Muscular Diseases (Myopathy) 12/2009 - 01/2004
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Nervous System Diseases (Neurological Disorders) 05/2016
1	Mania (Manias) 05/2016
1	Neuroblastoma 04/2015
1	Genomic Instability 12/2008
1	Major Affective Disorder 2 05/2007

Drug/Important Bio-Agent (IBA)

15	Cardiolipins (Cardiolipin)IBA 01/2022 - 01/2004
9	Inositol (Myoinositol)IBA 01/2022 - 10/2009
8	Valproic Acid (Depakote)FDA LinkGeneric 01/2020 - 09/2003
5	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 10/2004
4	Pharmaceutical PreparationsIBA 01/2020 - 11/2015
3	EnzymesIBA 01/2022 - 01/2020
3	LithiumIBA 05/2016 - 12/2004
2	LipidsIBA 01/2022 - 01/2009
2	monolysocardiolipinIBA 04/2016 - 01/2009
1	phytosphingosineIBA 01/2017
1	CeramidesIBA 10/2016
1	Protons (Proton)IBA 11/2015
1	Adenosine Triphosphatases (ATPase)IBA 11/2015
1	Therapeutic UsesIBA 11/2015
1	SphingolipidsIBA 11/2014
1	Phospholipases (Phospholipase)IBA 02/2014
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2012
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2012
1	Membrane Proteins (Integral Membrane Proteins)IBA 12/2009
1	Carboxylic AcidsIBA 05/2007
1	Anticonvulsants (Antiepileptic Drugs)IBA 05/2007
1	AcyltransferasesIBA 12/2005
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2004